GlassScriptPhysician profile
Rafael Rubalcava
NPI 1417978644
$5,561.21
in general payments reported to CMS, 2019-2025
34 companies · $931 in 2025
The $931 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $174 · 2021: $487 · 2022: $972 · 2023: $1,137 · 2024: $756 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,725 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,724.80 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,026.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $478.56 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $446.12 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $382.89 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Astrazeneca Pharmaceuticals LP | $339.88 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $339.75 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $313.87 | 2019-2022 | |
| Novo Nordisk INC | $294.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $268.41 | 2021-2025 | Qulipta |
| Pfizer INC. | $258.65 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $169.17 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.56 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $147.11 | 2024-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.65 | 2019-2025 | Jardiance |
| Almatica Pharma LLC | $113.56 | 2022-2023 | Loreev Xr, Sertraline Hcl |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $95.68 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $82.33 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $67.48 | 2024-2025 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $65.04 | 2021-2022 | |
| Alkermes, INC. | $55.72 | 2023 | Lybalvi |
| Lundbeck LLC | $40.25 | 2023-2024 | Rexulti |
| Allergan, INC. | $33.58 | 2019-2020 | |
| Shield Therapeutics INC | $33.28 | 2023 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $26.84 | 2022 | |
| Dexcom, INC. | $26.03 | 2021-2022 | |
| Hologic Sales and Service, LLC | $24.81 | 2025 | Thinprep 2000 Processor, Aptima |
| Genentech USA, INC. | $22.70 | 2019 | |
| Seqirus USA INC | $22.28 | 2024 | Flucelvax, Fluad |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.95 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $16.75 | 2019 | |
| Amarin Pharma, INC. | $14.52 | 2019 | |
| Boston Scientific Corporation | $14.14 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.61 | 2023 | Quviviq |
| Abbott Laboratories | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Rubalcava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.